REG - AstraZeneca PLC - AstraZeneca prices a €1.4bn bond offering

AstraZenecaAnnouncement

30/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240730:nRSd2872Ya&default-theme=true

RNS Number : 2872Y  AstraZeneca PLC  30 July 2024

 

30 July 2024 07:00 BST

 

 

AstraZeneca prices €1.4 billion bond offering

 

 

AstraZeneca PLC (the Company) announces that, on 29 July 2024, its wholly
owned subsidiary AstraZeneca Finance LLC, successfully priced two tranches of
Eurobonds totalling €1.4 billion (the Offering). The Offering is expected to
close on 5 August 2024, subject to customary closing conditions.

 

The Offering consisted of the following notes, issued by AstraZeneca Finance
LLC and fully and unconditionally guaranteed by the Company:

 

·    €650 million of fixed rate notes with a coupon of 3.121% maturing
on 5 August 2030; and

·    €750 million of fixed rate notes with a coupon of 3.278% maturing
on 5 August 2033 (together, the Notes).

 

The Company expects to use the net proceeds of the offering for general
corporate purposes.

 

BNP Paribas, Goldman Sachs International, Morgan Stanley and Société
Générale acted as joint book-running managers on the transaction.

 

The Notes will be issued under the US$10,000,000,000 EMTN programme of the
Company and AstraZeneca Finance LLC and admitted to listing on the UK
Financial Conduct Authority's Official List and to trading on the London Stock
Exchange's Main Market.

 

The Notes have not been registered under the U.S. Securities Act of 1933 and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration.

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the Notes described herein, nor shall there be any sale of
these Notes in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction.

 

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODBIGDRCBDDGSC